FDA delays review date for Epix' MRA (magnetic resonance angiography) agent
This article was originally published in Clinica
Executive Summary
The US FDA has delayed by three months a decision on whether to approve a magnetic resonance angiography (MRA)-based contrast agent for vascular imaging.